Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

• Päätekijät: Hsiangkuo Yuan (Tekijä), Fred Cohen (Tekijä), Maurice T Driessen (Tekijä), Lynda J Krasenbaum (Tekijä), Mario Ortega (Tekijä), Mary Hopkins (Tekijä), Michael J Marmura (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: SAGE Publishing, 2024-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observat...